TG and Rhizen to co-develop PI3K inhibitor
This article was originally published in Scrip
New York-based TG Therapeutics has licensed a phosphoinositide-3-kinase (PI3K) inhibitor of the delta pathway from Rhizen Pharmaceuticals of Switzerland that it hopes to position as one of the first PI3K therapies on the market for haematological malignancies and autoimmune disorders.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?